| Company | Type Of | Number Of | Amount | Investors; Placement Agents; |
| (Symbol) | Financing | Shares, Units | Raised (M) | Details (Date) |
| Or Warrants (M) | ||||
| Alliance | Private | 0.1S | $6 | Alliance sold 0.1M shares of convertible, |
| Pharmaceutical | placement | redeemable preferred stock at $60 each to | ||
| Corp. (ALLP) | 3 institutional investors led by Brown | |||
| Simpson Asset Management; the preferred | ||||
| shares are convertible into common stock | ||||
| at $6 per share through 1/3/99 and there- | ||||
| after at a price adjusted to market price; no | ||||
| dividends will accrue; CIBC Oppenheimer | ||||
| and Solomon Smith Barney advised the | ||||
| company in the transaction (8/17) | ||||
| HemaSure Inc. | Revolving | — | $5 | HemaSure received a commitment from a |
| (OTC Bulletin | line of credit | commercial bank for a $5M revolving line | ||
| Board:HMSR) | of credit; $3M will be available on signing, | |||
| with the rest available based on develop- | ||||
| ment milestones; the line of credit will | ||||
| expire in 6/00; Sepracor Inc., the company's | ||||
| largest shareholder, will guarantee the re- | ||||
| payment in exchange for the right to buy up | ||||
| to 1.7M shares of HemaSure at $0.69 per | ||||
| share (8/14) | ||||
| Medarex Inc. | Rights offer- | 3.7S | $25.1 | The Bay City Capital Fund I LP and vari- |
| ing to former | ous Pritzker family business interests | |||
| shareholders | (together, BCC Acquisition I LLC) bought | |||
| of GenPharm | the rights of former GenPharm International | |||
| International | Inc. shareholders to receive $25.1M shares | |||
| of Medarex common stock; the investors | ||||
| exchanged these rights for 3.72M shares of | ||||
| Medarex stock and warrants to purchase | ||||
| 0.45M shares at $10 each over 7 years; | ||||
| once the warrants are exercised, BCC | ||||
| Acquisition will hold a 15.8% stake | ||||
| in Medarex (8/5) | ||||
| Paracelsian Inc. | Exercise of | ND | $0.5 | Biomar International Inc., which received |
| (PRLN) | warrants | warrants as part of its 1/98 investment in | ||
| Paracelsian, exercised those for $0.52M in | ||||
| common stock (8/12) | ||||
| Shaman | Product | 0.14S | $14 | Shaman sold 0.14M shares of registered, |
| Pharmaceuticals | royalty-based | Series C convertible preferred stock at | ||
| Inc. (SHMN) | offering of | $100 per share in a public offering; the | ||
| preferred stock | stock entitles the holders to the greater of | |||
| a $10/year dividend, payable semi-annually | ||||
| in common stock, or a pro rata share of | ||||
| royalties on the company's net U.S. sales | ||||
| of Provir; Dakin Securities Corp. acted as | ||||
| the placement agent (8/19) | ||||
| Synsorb Biotech Inc. | Financing | — | $7.2 | Synsorb arranged 2 separate financing |
| (TSE:SYB; NASDAQ: | facilities | facilities; it arranged a US$3.3M agreement | ||
| SYBBF; Canada) | with the Canadian Bank of Commerce on | |||
| 8/20; this financing has a 5-year term and | ||||
| Synsorb pays interest until 2000; in the | ||||
| 2nd agreement, reached on 8/25, the com- | ||||
| pany secured a US$3.9M, 3-year financing | ||||
| agreement with Finova Capital Corp. | ||||
| (8/20; 8/25) | ||||
| Techniclone Corp. | Exercise of | 3.76S | $2.2 | Holders of warrants issued in conjunction |
| (TCLN) | warrants | with Techniclone's Class C preferred stock | ||
| financing exercised warrants for 3.76M | ||||
| shares, 3.42M of them for cash and the rest | ||||
| converted on a cashless basis (8/7) | ||||
| TOTAL: $60.0M | ||||
| NOTES: | ||||
| ND = Not disclosed, reported and/or available; S = Shares; U = Units; TSE = Toronto Stock Exchange; W = Warrants | ||||
| The financings in this chart include loans, bridge financings and other interim measures as well as sales of business units, debt offerings, rights offerings, exercises of warrants, institutional offerings of registered stock and standard private placements. | ||||
